摘要
目的:观察消癌顺气汤联合CAF化疗对肝郁气滞型乳腺癌患者疗效及T细胞亚群影响。方法:将2012年1月—2014年12月在本院就诊的肝郁气滞型乳腺癌患者165例,随机分为3组各55例,对照A组未行化疗治疗,对照B组行CAF化疗治疗,研究组行CAF化疗联合消癌顺气汤治疗,比较3组患者临床疗效。结果:对照B组、研究组有效率、生活质量评分均高于对照A组,但是研究组提高幅度更大,且高于对照B组(P<0.05,P<0.01);治疗后对照A组、研究组与对照B组CD4+、CD4+/CD8+指标水平均较治疗前改善,对照B组治疗后与治疗前比较差异显著(P<0.05)。结论:消癌顺气汤联合CAF化疗治疗肝郁气滞型乳腺癌患者疗效良好,且不会对T细胞亚群产生不良影响,还可以改善患者生活质量。
Objective： To observe the influence of Decoction for Xiaoai Shunqi（ DXASQ） in combination with CAF chemotherapy on efficacy and T sub-cell group of patients with breast cancer of liver and qi stagnation. Methods： One hundred and sixty-five patients with breast cancer of liver and qi stagnation who were treated in our hospital between Jan. of 2012 and Dec. of 2014 were chosen and randomly divided into 3 groups,with 55 cases in each group. The ones in the A control group didn＇t receive chemotherapy,while the ones in the B control group were treated with CAF chemotherapy,and the ones in the research group were added DXASQ based on CAF chemotherapy. Then the clinical curative effects of the three groups were compared. Results： The effective rate and life quality score of the B control group and the research group were all higher than those of the A control group,but the improved range of the research group was bigger and higher than that of the B control group（ P〈 0. 05,P〈 0. 01）. After the treatment,CD4 ＋,CD4 ＋ / CD8 ＋ levels of the A control group,the research group and the B control group were all improve;and there were significant differences before and after the treatment in the B control group（ P〈 0. 05）. Conclusion： DXASQ in combination with CAF chemotherapy has remarkable clinical curative effect on breast cancer of liver and qi stagnation,and has no bad influence on T sub-cell group. What＇s more,it can improve the patients＇ life quality.
出处
《河南中医》
2016年第2期283-285,共3页
Henan Traditional Chinese Medicine
关键词
乳腺癌
肝郁气滞证
消癌顺气汤
CAF化疗
breast cancer
liver and qi stagnation
Decoction for Xiaoai Shunqi（DXASQ）
CAF chemotherapy
